Esmo plenary 2023. 1016/S0923-7534(23)01940-3.

• Esmo plenary 2023 The ESMO Virtual Plenaries are presentations of original scientific data from interventional clinical trials (phase I/II/III) that either shape clinical practice or provide groundbreaking insights in the biology of disease/mechanisms of Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study. Session date: 15-16 February 2024. Learning objectives include updating knowledge in early Oct 21, 2023 · According to patient-reported outcomes (PROs) results presented at the ESMO Congress 2023 (Madrid, 20–24 October), dostarlimab plus chemotherapy was associated with improvements over placebo plus chemotherapy in the 118 patients in the RUBY trial with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or ESMO Virtual Plenary: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) ESMO Congress 2023. ESMO Colloquium supported by Novocure: Therapeutic applications and synergies of electric fields in oncology Watch the session. Clinical trial identification. Search ESMO; Meeting Calendar; OncologyPRO; As of 21 Aug 2023 (median follow-up: 22. Amivantamab (ami), an EGFR-MET bispecific antibody with immune cell-directing activity, plus carboplatin-pemetrexed (chemo) with and without lazertinib (laz), a CNS-penetrant, 3 rd-gen EGFR TKI, have demonstrated antitumor activity in phase 1 studies. 94MO - The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving Slides and webcasts from ESMO Academy are reserved to ESMO Members and registered participants according to the presenters' agreement to release them. The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology. 2) OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S895-S924. 1016/S0923-7534(23)01935-X. 11 July 2024 12 July 2024 18:30-19:30 CEST Welcome and introduction, Scientific background and Data presented at the ESMO Virtual Plenary in November confirm the importance of checkpoint and VEGF inhibition in metastatic, recurrent or persistent cervical cancer (R/M CC). Of ESMO virtual plenary abstracts Annals of Oncology. Login ; Abstract 740MO Feb 15, 2024 · Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders. Virtual Plenary Expert Insights: Webcast of 27 March presentations, Discussion and Q&A (ii) Faculty and online audience. Madrid, Spain. VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC) As of 21 Aug 2023 (median follow-up: 22. Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. 0 mo), 453 patients were randomized (TIS, n=226; placebo, n=227). Login ; OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Virtual Plenary; ESMO Courses; Become a member . 2023 ASCO Annual Meeting. Abstract VP3-2023. Authors T. Oct 20, 2023 · OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, ESMO Virtual Plenary; ESMO Courses; Become a member . Conclusions. 03 μg/kg) of BI 764532 (RA n=24; Background. Login ; Abstract 402P. OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, ESMO Immuno-Oncology Congress 2023. Login ; Abstract 1039P. - HCC illuminated: Exploring future frontiers with systemic immunotherapies. Presenter: M. Login ; Abstract LBA10 Oct 21, 2023 · OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, ESMO Congress 2023; Mini oral session - Head and neck cancer. It is Abstract Book of the ESMO Congress 2023. Slides and webcasts are reserved to ESMO Members and Please set up your ESMO Account now to access the ESMO Virtual Plenary. 0 mo), 453 patients were Add to Calendar 12-02-2025 18:30 12-02-2025 19:30 Europe/Paris ESMO Virtual Plenary: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial More info on OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S619-S650. The hallmarks of cancer in 2023. Login ; OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Congress 2023; The hallmarks of cancer in 2023. As such, and in light of the tragic events unfolding in so many parts of the world, ESMO will not accept responsibility for any OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S507-S542. Login ; Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S619-S650. MARIPOSA-2 (NCT04988295) evaluated these combinations in EGFR-mutated (Ex19del or L858R) OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S1202-S1228. Login ; Featured ESMO Congress 2024. Nov 6, 2023 · The open-label randomised phase 3 BEATcc academic trial (NCT03556839) evaluated atezo (anti-PD-L1) combined with first-line chemotherapy (CT) + bev for R/M CC, irrespective of PD-L1 status. Login ; Abstract 1042P. 1, 2022 — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical Abstract. Login ; Abstract 895P. Hochmair1, K. 1016/S0923-7534(23)01924-5. Session date: 16-17 February 2023. Slamon DJ, Stroyakovskiy D, Yardley DA, et al: Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2– early breast cancer: Primary results from the phase III NATALEE trial. Chair: Keiichi Fujiwara, Saitama Medical University International Medical Center, Saitama, Japan Mansoor Mirza, Rigshospitalet – Copenhagen University Hospital, Copenhagen, Denmark ESMO Virtual Plenary: 3 November 2023. Nowecki3, Jan 12, 2024 · ESMO VIRTUAL PLENARY ABSTRACTS VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC M. ESMO Meetings; ESMO Virtual Plenary; ESMO Courses; Become a member . Fasching1, D. 1016/S0923-7534(23)01930-0. Solange Peters Virtual Plenary Expert Insights: Webcast of 15 February presentations, Discussion and Q&A (ii) Faculty and online audience. Login ; Abstract LBA23 Nov 16, 2023 · Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders. Date 24 Oct 2023. Plenary presentation: Expanding OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, ESMO Virtual Plenary; ESMO Courses; Login ; Dr Michiel van der Heijden reports on key results from ESMO Congress 2023 on the CheckMate 901 trial. Resources are available according to the presenters' agreement to release them. Nov 19, 2021 · A presentation in an ESMO Virtual Plenary session during the ESMO Asia Virtual Oncology Week 2021 reports an encouraging, albeit small, improvement in progression-free survival (PFS) with sintilimab in combination Oct 21, 2023 · OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S1152-S1189. Login ; Abstract 75MO. Login ; Abstract 670P. Resources: Slides . Editorial acknowledgement. Live on: Virtual Plenary: 12 February 2025 ESMO Virtual Plenary: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in Jul 15, 2022 · Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders. Login Gynecologic Oncology, Virginia Commonwealth University Medical College of Virginia Campus, 23298 - Richmond/US ESMO Webinars ESMO Guidelines: Real World Cases - Webinar Series: Renal Cell Carcinoma 2025. The copyright protected educational resources from this event are for personal usage only and not to be shared with any third parties. Scienti fic Track Member Gynaecological Cancers ESMO 2018, ESMO 2020, ESMO 2022. Chair: David SP Tan, NUHS - National University Health System, Singapore Mansoor Mirza, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S278-S324. Dec 3, 2023 · OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, ESMO Asia Congress 2023; Mini oral session 2: Gastrointestinal tumours. 21/10/2023 Session: ESMO Colloquium supported by Eisai Europe Ltd. Weber3,Y. (ESMO) Virtual Plenary (Abstract VP1-2023). VP2 Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. Login ; Financial Interests, Personal, Invited Speaker, June 2022 and June 2023 during ESMO GI meeting: Seagen; Financial Interests, Personal, Writing Engagement, Contract of consulting 2021 and 2022 and 2023: MSD Oncology; Financial Interests, Personal, Advisory Board, September 2022: OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S1013-S1031. Login ; Dr Yelena Janjigian reports on key results from ESMO Congress 2023 on the MATTERHORN study. SHR-1701, a novel bifunctional fusion protein targeting PD-L1 and TGFβ, may enhance antitumor activity in Background. J. Mar 16, 2022 · Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders Member of the Committee: ESMO Guidelines Committee; Officer, Committee Member: ESMO 2023 Scientific Committee; Product Samples, Institutional, Responsible for care of patients receiving Olaparib on named patient programme in Breast Cancer @ Guy's London OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S1254-S1335. Background. VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Virtual Plenary; ESMO Courses; Become a member . Topics Tumour Site ESMO Virtual Plenary; ESMO Courses; Become a OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S619-S650. Friday 20: MATTERHORN and KEYNOTE-A18 Saturday 21: LITESPARK-005, ALINA, LIBRETTO-431 and LIBRETTO-531 Sunday 22: CodeBreak 300, innovaTV 301 and CheckMate 901 Monday 23: DESTINY-PanTumor02, MARIPOSA-2, TROPION-Lung01 and PSMAfore study Abstract. 7–84. 22 Oct 2023. BEGONIA (NCT03742102) is an ongoing 2-part, open-label platform study in 1L a/mTNBC, evaluating D, an anti–PD-L1 antibody, plus novel therapies, including Dato-DXd, an antibody-drug conjugate made of a anti-TROP2 antibody covalently linked via a cleavable linker to a topoisomerase I inhibitor payload. Session: Opening session Palliative and Supportive Care Sessions at ESMO Congress 2023 Madrid; 2024 ESMO Designated Centres; Palliative and Supportive Care Sessions at ESMO Congress 2024 Barcelona; In selected Virtual Plenary sessions, ESMO will collaborate with the AACR to identify discussants of clinical and biological perspectives in presented studies. Virtual Plenary Expert Insights: Webcast of 14 July presentations, Discussion and Q&A (ii) Chair: Elaine Lim Hsuen, NCCS - National Cancer Centre Singapore, Singapore. Presented September 14, 2023. 0 mo), 453 pa-tients were randomized (TIS, n¼226; placebo, n¼227). Slamon2, Z. Epidemiology and Surveillance. OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S1032-S1061. OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Asia Congress 2023; Latest updates in drug development. Presented June 4, 2023. Login ; Abstract 2255P Feb 21, 2023 · ESMO VIRTUAL PLENARY ABSTRACT VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study S. OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Congress 2023; Mini oral session - Gynaecological cancers. Login ; Abstract 2015P. 1016/S0923-7534(23)01939-7. Chair: Ross Soo, NCIS - National University Cancer Institute Singapore, Singapore Dongsheng Yue, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China Apr 1, 2023 · The European Lung Cancer Congress 2023 provides insights into the prevention, diagnosis, biology and multi-disciplinary management of thoracic malignancies. ESMO Virtual Plenary. Authors ESMO Virtual Plenary; ESMO Courses; Become a member . Raludotatug deruxtecan（R-DXd） is an antibody-drug conjugate (ADC) targeting CDH6 with a topoisomerase I inhibitor (DXd) as a payload which is being developed for several malignancies, including epithelial ovarian cancer Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders. OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Virtual Plenary; ESMO Courses; Become a member . New antibody drug conjugate (ADC) targets on the horizon. Median follow-up at data cutoff (Jan 24, 2023) was 51. 1016/S0923-7534(23)01944-0. Future Directions for ADCs in Urothelial Cancer. Login ; OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Session: Virtual Plenary Debate. 118O - Definitive results for NSCLC and Bladder cancer cohorts in the phase 2a trial of visugromab Background. OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Congress 2023; Scientific Congress Highlights 2. Satellite webcasts from our Industry partners. 01 - 03 Dec 2023. 1, 2022 — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will May 10, 2023 · ESMO Congress 2023 Abstract submission regulations & instructions investigator represents an independent entity contracted by the sponsor, this should be disclosed in the abstract submission process. OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S1254-S1335. OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Congress 2023; Seagen - ADCs’ Potential Across Tumors. Date 21 Oct 2023. Watch session. OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Congress 2023; Proffered Paper session 1 - Gastrointestinal tumours, upper digestive ESMO Virtual Plenary; ESMO Courses; Become a member . 3. Rha1, L. 11 Jul 2024 - 12 Jul 2024. Invited Discussant LBA43, 740MO, 742MO and 741MO. Chair: David SP Tan, NUHS - National University Health System, Singapore Mansoor Mirza, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. May 11, 2023 · OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, ESMO Virtual Plenary; ESMO Courses; Become a member . Presenter: Isabelle Ray-Coquard. Median age was 64 yrs (range: 23–83) & 74% were male. The standard 1L therapies for mCRC involve a fluoropyrimidine with oxaliplatin and/or irinotecan, and a biologic agent. 1016/S0923-7534(23)01926-9. Restoring p53 by Antagonizing MDM2-p53 in Soft Tissue Sarcoma. 2. Of these, 452 received neoadjuvant treatment OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S1254-S1335. OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S410-S457. 17 Sep 2021. 14 - 15 Sep 2023 Virtual Meeting ESMO Virtual Plenaries ESMO Virtual Plenary with AACR Expert Commentary: September 2023. Login ; OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S554-S593. Member of Gynaecological Cancers Fac-ulty and Subject Editor Gyn ESMO Guidelines: ESMO; Non-Financial Interests, Leadership Role, ESMO GYN Co-Chair 2023 - 2025: ESMO; Non-Financial Interests, Leadership Nov 3, 2023 · Data presented at the ESMO Virtual Plenary in November confirm the importance of checkpoint and VEGF inhibition in metastatic, recurrent or persistent cervical cancer (R/M CC). Date 03 Dec 2023. ESMO Virtual Plenary; ESMO Courses; Become a As of 21 Aug 2023 (median follow-up: 22. The BEATcc phase III trial reported the benefits of atezolizumab combined with the VEGF inhibitor bevacizumab and chemotherapy as a first-line treatment for R/M CC. Dec 1, 2023 · ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe. Given different targets, payloads with non-overlapping toxicities and preclinical synergy of SG with anti-microtubule agents, we evaluated the safety and efficacy of SG+EV in a phase I trial (NCT04724018). Authors N. Certify that the study reported in the abstract will not be presented as such during the ESMO Congress 2023 at any industry- New this year, the Virtual Plenary Debate session taking place on Friday 17 September at the ESMO Congress 2021 will be the ideal debating time for the oncology community to think around the latest key studies presented at the ESMO Virtual Plenaries. The BEATcc phase III trial reported the Jul 11, 2024 · ESMO Virtual Plenary: Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma . We report OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S1152-S1189. These interim results are based on the 12 Apr 2022 data cutoff; final results will be shown at ESMO 2023. Advertisement. Login ; Abstract 2311P Jul 11, 2024 · Data presented at the ESMO Virtual Plenary in July 2024 confirm the antitumour activity of the combination of eftilagimod alpha, a soluble LAG-3 protein and major histocompatibility complex (MHC) class II agonist, and the anti-PD-1 pembrolizumab as first line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma Oct 21, 2023 · OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S1062-S1079. Login ; OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S458-S497. V. Login ; Abstract LBA17. Session date: 17-18 November 2023. Non OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Congress 2023; Janssen Pharmaceutica N. From a keynote lecture pinpointing the hallmarks of cancer in the current ESMO Asia Congress 2023. Date 23 Oct 2023. ESMO Asia Congress 2023; Satellite Symposia Webcasts; F. Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial Huiping Li, Peking University Cancer Hospital and Institute, Beijing, The ESMO 2023 Programme is now online! Access the online programme. Results of the interim analysis of KEYNOTE-859 are in, and they confirm the overall survival benefit of first-line immunotherapy plus chemotherapy in advanced gastric cancer. Y. 06 - 08 Dec 2023. 1016/S0923-7534(23)01940-3. 20 - 24 Oct 2023. E. ESMO Colloquia slides & webcasts. Feb 16, 2023 · ESMO Virtual Plenary Abstract Volume 34, Issue 3 p319-320 March 2023 Open Archive. Monthly presentations of the latest, original scientific data from randomized phase III trials in oncology, or from phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or Oct 20, 2023 · DISCLAIMER ESMO is a scientific and professional, non-political and non-religious organisation. LBA7 - Nivolumab plus gemcitabine Dec 15, 2022 · ESMO Virtual Plenary Abstract Annals of Oncology Title VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial Oct 21, 2023 · OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, ESMO Virtual Plenary; ESMO Courses; Become a member . Antibody-drug conjugates are a mainstay in treatment of mUC. RUBY is a phase III, global, PD-1 inhibitors in combination with chemo have shown efficacy in G/GEJ cancer. ESMO virtual plenary abstracts Volume 35, Issue 3 p332-333 March 2024. 1016/S0923-7534(23)01938-5. Practice changing data and high quality education in all tumour types, therapeutic innovations, translational ESMO Virtual Plenary Resources. a NIVO vs IPI (Stratified Cox proportional hazards model). b In stage III patients (NIVO = 307; IPI = 366). A comprehensive educational and scientific programme will foster exchange and debate of translational cancer science, showcase first announcements of potentially practice changing data and stimulate multidisciplinary discussions to improve treatment options for our patients. Login ; Abstract LBA74 Check out who is attending exhibiting speaking schedule & agenda reviews timing entry ticket fees. May 25, 2023 at 7:27 am SHANGHAI and CAMBRIDGE, Mass. 1016/S0923-7534(23)01937-3. Rha SY, Wyrwicz LS, Yañez-Weber PE, et al. Title: VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab ESMO Virtual Plenary; ESMO Courses; Become a member . Zai Lab to Present Interim Overall Survival Results for ZEJULA® (niraparib) from the Phase 3 NORA Study at the ESMO Virtual Plenary. Login ; Abstract 663P. This abstract is presented as part of the ESMO Virtual Plenaries programme (https: LUGANO, Switzerland – Under the promise to “Disseminating innovative research for optimal cancer care” as this year’s tagline reads, the ESMO Congress 2023 will be held in Madrid between 20-24 October 2023 with a virtual component to allow as many people as possible to attend. S. Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: phase III Posted: 2/21/2023 11:51:00 AM Last Updated: 2/24/2023 10:41:07 AM. GI, upper digestive: HPB. Login ; Abstract 2376P. (1) Mar 27, 2023 · ESMO VIRTUAL PLENARY ABSTRACT VP2-2023: DostarlimabDchemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)- Nov 6, 2023 · ficer, Chair of Gynaecological Track ESMO 2019. Date 22 Oct 2023. 18:30-19:30 CET. Use of anti–PD-1s with chemo has improved outcomes in multiple tumour types. Login ; Abstract 1885P. Author affiliations. A. Geneva, Switzerland. Certify that the study reported in the abstract will not be presented as such during the ESMO Congress 2023 at any industry- Mar 27, 2023 · These clinically meaningful results from the Phase 3 RUBY trial (ENGOT-EN6-NSGO/GOG3031) are the first confirmation of the benefits of immunotherapy in this patient population, and were reported at the ESMO Virtual Plenary on 27 March 2023. Login ; Abstract 550O. 7 (range, 32. 138MO - Pembrolizumab (Pembro) or placebo (Pbo) ESMO Virtual Plenary; ESMO Courses; Become a member . OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S458-S497. OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Congress 2023; ESMO Virtual Plenary; ESMO Courses; Become a member . It is a 5 day event organised by ESMO - European Society for OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S1152-S1189. Presenter: Patrick May 25, 2023 · Zai Lab to Present Interim Overall Survival Results for ZEJULA® (niraparib) from the Phase 3 NORA Study at the ESMO Virtual Plenary. Abstracts and ePosters are open access. 21 Oct 2023. 1317MO - Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC) Background. 02 Dec 2023. ESMO thanks the authors for their generosity. OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S278-S324. LBA73 - Pathological complete Feb 15, 2024 · Virtual Plenary Expert Insights: Webcast of 15 February presentations, Discussion and Q&A (ii) Faculty and online audience. Welcome and introduction, Scientific background and context. 10. The copyright protected Sep 29, 2023 · ESMO VIRTUAL PLENARY ABSTRACT VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HRD/HER2- early breast cancer (EBC) P. ESMO Award 2023. Vermaelen2, G. Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state of art management and Virtual Plenary Expert Insights: Webcast of 15 December presentations, Discussion and Q&A (ii) Faculty and online audience. Login ; OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Asia Congress 2023; Practicing oncology across the globe: ESMO Virtual Plenary; ESMO Courses; Become a member . We present results of the double-blind, placebo-controlled KEYNOTE-859 study of pembro + Friday 3 November 2023. “Science is moving faster than ever”, explained ESMO President Prof. Login ; Abstract 1278P. Find webcasts, slides, abstracts and ePosters from ESMO Meetings and educational courses. ESMO Virtual Plenary; ESMO Courses; Become a member . OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Congress 2023; Mini oral session - Breast cancer, metastatic. Login ; For healthcare professionals, researchers, and those interested in the ever-evolving field of cancer research and care. Singapore, The ESMO Asia Congress covers breakthroughs on the most prevalent cancer types in the region, and offers high quality multidisciplinary educational sessions, ESMO Virtual Plenary; ESMO Courses; Become a member . Login ; Professor Ben Solomon reports on key results from ESMO Congress 2023 on LBA2 - ALINA: efficacy and safety of adjuvant alectinib Feb 15, 2024 · ESMO virtual plenary abstracts Volume 35, Issue 3 p332-333 March 2024. Login ; Resources from the same session. 1016/S0923-7534(23)01271-1. OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S594-S618. Invited Discussant LBA9, 515MO and 516MO. As of 26 March 2023, 107 pts received ≥1 dose (≥ 0. OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Meetings; ESMO Virtual Plenary; ESMO Courses; Become a member . 1016/S0923-7534(23)01943-9. , Dec. Session ESMO Virtual Plenary; ESMO Courses; Become a member . Search ESMO; Meeting Calendar; OncologyPRO; VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC. Login ; Abstract 263P. Invited Discussant 379MO and 380MO. Authors ESMO Meetings; ESMO Virtual Plenary; ESMO Courses; Become a member . Reig, ES. Login ; Abstract 2304P Oct 21, 2023 · OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S1152-S1189. Bai4, Feb 15, 2024 · Perioperative use of the anti-PD-1 monoclonal antibody tislelizumab improves responses at the time of surgery and reduce the risk of disease recurrence in patients with early-stage resectable non-small cell lung cancer (NSCLC), as confirmed by updated results from the RATIONALE-315 (NCT04379635) presented at the ESMO Virtual Plenary in February 2024. Login ; 11 May 2023. 1016/S0923-7534(23)01927-0. Login Dec 15, 2023 · OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, ESMO Virtual Plenary; ESMO Courses; Become a member . Song. VP1-2024: RATIONALE-315: Event-free survival As of 21 Aug 2023 (median follow-up: 22. Programme . Login ; Abstract 65O. Cadherin-6 (CDH6) is a transmembrane glycoprotein, whose aberrant expression has been reported in several human carcinomas. 20 Oct 2023. Carboplatin-paclitaxel (CP) is standard of care (SOC) for first-line treatment of primary A/R EC; median OS is <3 yrs. . Login ; OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S755-S851. 1016/S0923-7534(23)01936-1. Chair: Ross Soo, NCIS - National University Cancer Institute Singapore, Singapore Dongsheng Yue, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. We present results of the double-blind, placebo-controlled KEYNOTE-859 study of pembro + Session: Illumina - Detection of homologous recombination deficiency (HRD): Role of HRD testing and impact on patient management. Session: Session 1 OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S594-S618. Mountzios3, E OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S732-S745. Search ESMO; Meeting Calendar; From Apr 2022-Oct 2023, 33 pts enrolled, including 31 evaluable pts. Webcast. Login ; Abstract 654O. RUBY (NCT03981796) evaluated the efficacy and safety of the anti–PD-1 dostarlimab (D)+CP in A/R EC compared with CP alone. 1016/S0923-7534(23)01265-6. Professional medical writing and editorial assistance were provided by Jessica Augello, PhD, and Michele Salernitano of Ashfield MedComms, an Inizio company, and funded by Bristol Myers Squibb. 1016/S0923-7534(23)04149-2. The ESMO 2024 comprehensive educational and scientific program fostered exchange and debate on translational cancer science, presented groundbreaking data, and encouraged multidisciplinary discussions to improve patient treatment. Welcome and introduction Toni Choueiri; Current and emerging clinicopathologic and molecular prognostic schemes for patients with advanced renal cell carcinoma OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S852-S886. 10. Wyrwicz2, P. 1016/S0923-7534(23)01258-9. Login ; OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Congress 2023; Presidential 3. Login ; Abstract LBA21 OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S1254-S1335. Login ; Abstract 1373P. 1016/S0923-7534(23)01925-7. Series objectives: To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews. PD-1 inhibitors in combination with chemo have shown efficacy in G/GEJ cancer. Search ESMO; Meeting Calendar; OncologyPRO; VP1-2023: Pembrolizumab (pembro) plus chemotherapy OncologyPRO is the home of ESMO’s educational & scientific resources, ESMO Asia Congress 2023; Mini oral session 2: Thoracic cancer. VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study. Invited Discussant 859MO, 860MO and LBA47. 2023 edition of ESMO Virtual Plenary will be held at Madrid starting on 20th October. 1177 pts in the ITT population, 590 were randomized to pembro and 587 to pbo. Hoffmann-La Roche Ltd. May 9, 2024 · Welcome and introduction, Scientific background and context Giampaolo Bianchini, IRCCS Ospedale San Raffaele, Milan, Italy. Access resources. Login ; Abstract 2308P. 06 Dec 2023. Login ; Abstract 1032P. ESMO Congress 2023 Abstract submission regulations & instructions investigator represents an independent entity contracted by the sponsor, this should be disclosed in the abstract submission process. NCT02388906. Invited Discussant LBA14 and LBA15. Abstract LBA500. Login ; Abstract 1511O. VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study Oct 22, 2023 · OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, ESMO Virtual Plenary; ESMO Courses; Become a member . Published: November 16, 2023 Mar 27, 2023 · Data presented at the ESMO Virtual Plenary in March 2023 provided the first confirmation that adding immunotherapy to standard chemotherapy for first-line treatment of advanced or first recurrence of OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Annals of Oncology (2023) 34 (suppl_2): S1254-S1335. OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S507-S542. Login ; OncologyPRO is the home of ESMO’s educational & scientific resources, Annals of Oncology (2023) 34 (suppl_2): S1254-S1335. 27 - 28 Mar 2023 Virtual Meeting Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. Optimising outcomes for patients with advanced renal cancer. Isabelle Ray-Coquard, Centre Léon Bérard, Lyon, France Check out who is attending exhibiting speaking schedule & agenda reviews timing entry ticket fees. Session Presidential 3. 15 Dec 2023. mkomk zqrb ysrle kifun wemq derfam hnukls sfj zzsrzlp qelfn